# Syndax Pharmaceuticals (SNDX) Investor Outlook: Exploring a 63% Potential Upside in the Biotech Arena

- Link: https://www.directorstalkinterviews.com/syndax-pharmaceuticals-sndx-investor-outlook-exploring-a-63-potential-upside-in-the-biotech-arena/4121245558
- Published: 2026-03-20T11:25:25+00:00
- Author: Madison Wilson

For investors with an eye on the biotechnology sector, Syndax Pharmaceuticals, Inc.(
NASDAQ: SNDX) presents a compelling opportunity, underscored by a potential upside
of 63.26%. With a market capitalisation of $2.12 billion, this healthcare company
is making significant strides in cancer therapy development, offering promising 
prospects for growth-oriented investors.

Syndax Pharmaceuticals operates in the dynamic biotechnology industry, focusing 
on innovative therapies for cancer treatment. At the forefront of its product lineup
is Revuforj (revumenib), a menin inhibitor targeting relapsed or refractory acute
leukemia. Additionally, the company is advancing Niktimvo (axatilimab-csfr) to address
chronic graft-versus-host disease, alongside other noteworthy developments like 
Entinostat, an HDAC inhibitor.

Despite its current price of $24, which hovers near the upper limit of its 52-week
range ($8.73 to $24.44), Syndax offers a notable growth trajectory. Analysts have
set an average target price of $39.18, suggesting substantial room for appreciation.
Notably, the analyst sentiment is overwhelmingly positive, with 12 buy ratings and
no hold or sell recommendations, a testament to the confidence in the company’s 
potential.

Syndax’s financial metrics paint a picture of a company in the growth phase. The
absence of a trailing P/E ratio and the rather negative forward P/E of -151.75 reflect
a company investing heavily in research and development, characteristic of many 
biotech firms focused on long-term breakthroughs. The impressive revenue growth 
rate of 794.90% indicates Syndax’s ability to scale its operations and potentially
generate significant future returns.

However, investors should be aware of the risks inherent in biopharmaceutical investments.
The company’s current EPS stands at -3.29, with a return on equity of -161.83%, 
highlighting ongoing challenges in reaching profitability. Furthermore, the free
cash flow is currently negative at -$210 million, underscoring the capital-intensive
nature of drug development.

From a technical perspective, Syndax exhibits some intriguing signals. The stock’s
50-day moving average is $21.46, and the 200-day moving average is $16.41, indicating
a positive short- to mid-term trend. However, a relative strength index (RSI) of
32.38 suggests the stock is nearing oversold territory, potentially indicating a
buying opportunity for value-seeking investors.

Syndax’s strategic focus on partnerships such as the agreement with Eddingpharm 
International for Entinostat further strengthens its pipeline and expands its market
reach. As the company continues to innovate and collaborate, its position in the
biotech landscape could become increasingly influential.

For investors with a tolerance for risk and a focus on long-term growth, Syndax 
Pharmaceuticals offers an intriguing proposition. The company’s commitment to pioneering
cancer treatments, combined with strong analyst support and a significant potential
upside, makes SNDX a stock worth watching closely as it navigates its path to future
success.

Share on: